Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitis, atópísk - aðrar húðsjúkdómar - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - ristilbólga, þvagsýrugigt - Ónæmisbælandi lyf - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - liðagigt, liðagigt - Ónæmisbælandi lyf - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - Ónæmisbælandi lyf - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited  - pazópaníb - krabbamein, nýrnafrumur - Æxlishemjandi lyf - nýrna-klefi krabbamein (rcc)votrient er ætlað í fullorðnir í fyrsta-línu meðferð háþróaður nýrna-klefi krabbamein (rcc) og fyrir sjúklinga sem hafa fengið áður en frumuboða meðferð fyrir háþróaður sjúkdómur. mjúkur-vefjum sarkmein (l)votrient er ætlað fyrir meðferð fullorðinn sjúklinga með vali flokkar af háþróaður mjúk-vefjum sarkmein (l) sem hafa fengið áður en lyfjameðferð fyrir sjúklingum sjúkdóm eða sem hafa gengið innan 12 mánuðum eftir (neo)viðbótar meðferð. verkun og öryggi hafa aðeins verið stofnað í ákveðnum l vefja æxli flokkar.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

amryt pharmaceuticals dac - lomitapide - kólesterólhækkun - lipid breytandi lyf - hvert er ætlað sem viðbót til að lágt‑feitur mataræði og öðrum fitu‑lækka lyf með eða án lágt-þéttleiki-lípóprótein (gegn) apheresis í fullorðinn sjúklinga með tilbúin ættingja hypercholesterolaemia (hofh). erfðafræðilega staðfestingu á hofh ætti að vera fæst þegar það er mögulegt. annars konar aðal hyperlipoproteinaemia og efri veldur hypercholesterolaemia (e. nýrungaheilkenni, of) verður að vera útilokað.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

theravia - dexametason - mergæxli - barksterar til almennrar notkunar - meðferð við mörgum mergæxli.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - vinorelbinum tvítartrat - innrennslisþykkni, lausn - 10 mg/ml

Evrópusambandið - íslenska - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriasis - Ónæmisbælandi lyf - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - fluconazolum inn - hart hylki - 150 mg